Investment Highlights from Cocrystal Pharma's Recent Placement
Recently, Cocrystal Pharma, Inc. (NASDAQ: COCP) successfully completed a private placement that raised $1.03 million. This investment, priced at $1.39 per share, included the issuance of 743,024 shares of common stock and warrants to buy up to 1,486,048 additional shares. The warrants, set at an exercise price of $1.24, can be exercised immediately and will remain valid for 27 months. Such robust participation from directors and management not only underscores their confidence in the company's mission but also sows trust among existing and potential investors.
Key Investors in the Private Placement
The investment cohort features notable figures such as Phillip Frost, M.D., who co-founded Cocrystal and serves as Chairman and CEO of OPKO Health, Inc. Other substantial contributors include Fred Hassan, Chairman of Caret Group and a director with Warburg Pincus, alongside Richard Pfenniger and James Martin, who is both co-CEO and CFO of Cocrystal. This alliance among experienced executives accentuates a collective commitment to advancing Cocrystal’s groundbreaking antiviral therapies.
Future Opportunities and Clinical Advancements
With the investment now secured, there remains potential for an additional $1.8 million should the warrants be fully exercised. While the future is inherently uncertain, the additional capital will potentially bolster the company’s clinical development programs, aiding in their pursuit of innovative antiviral solutions to combat pressing global health challenges.
Understanding Cocrystal's Mission and Vision
Cocrystal Pharma operates as a clinical-stage biotechnology firm, focusing on creating advanced antiviral treatments. Their innovative approach addresses significant unmet medical needs for diseases like influenza, viral gastroenteritis, COVID-19, and hepatitis. Utilizing unique structure-based technologies and drawing on Nobel Prize-winning expertise, Cocrystal strives to develop effective antiviral medications. This commitment is reflected in the excitement surrounding their recent investments, which are anticipated to support ongoing research and development efforts.
Investor Relations and Communication
For those interested in following Cocrystal Pharma's journey, the company remains transparent in its communications. Investors can reach out to their Investor Relations representative, Jody Cain at Alliance Advisors, via phone at 310-691-7100 or through email. Cocrystal is dedicated to keeping stakeholders informed about its progress and clinical advancements, fostering an environment of trust and collaboration.
Frequently Asked Questions
What was the amount raised in Cocrystal Pharma's private placement?
The company raised $1.03 million through a private placement of shares and warrants.
Who are the key investors involved in this private placement?
Key investors include Phillip Frost, M.D., Fred Hassan, Richard Pfenniger, and James Martin, who is a co-CEO and CFO of Cocrystal.
What will the proceeds from the private placement be used for?
The proceeds will support Cocrystal's clinical development programs and general corporate purposes.
What are the potential future proceeds from the warrants?
If fully exercised, the warrants could generate an additional $1.83 million for the company.
What is Cocrystal Pharma's focus as a biotechnology company?
Cocrystal focuses on developing innovative antiviral treatments to address significant unmet healthcare needs.
